Grant ID RP160813
Awarded On May 18, 2016
Title Nanoparticle Prophylaxis for Protection from Chemotherapy Ototoxicity
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization Acelerox
Principal Investigator/Program Director Dev Chatterjee
Cancer Sites Brain and Other Nervous System, Head and Neck, Lymphoma
Contracted Amount $195,665
Lay Summary

Cisplatin chemotherapy compounds kill cancer cells by damaging DNA preventing the cancer from growing. Due to its curative successes cisplatin is a standard of care for a broad spectrum of cancers, including cancers of the brain, breast, blood, kidney, colon, lung and head and neck, among others. Undesirable acute and long lasting side effects cause patients to terminate cisplatin treatment or to choose less effective treatments because of damage to normal functioning non-dividing cells and organs–such as in the hearing and balance organs. In >60% of pediatric lymphoma patients dose-escalating cisplatin therapy damage to the hearing and balance systems (called ototoxicity) leads to progre...

Read More